

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

Index

- abuse, and pelvic pain 109
- acupuncture 87
- Addison's disease 120
- adenomyosis 92
 - dysmenorrhoea 84–5
 - heavy menstrual bleeding 12
 - pelvic pain 106
- adhesions, chronic pelvic pain 106
- adjuvant analgesics 111–12
- alternative therapies
 - see* complementary and alternative therapies
- amenorrhoea
 - hormonal induction 97–8
 - investigation 18
 - primary 117, 119
 - secondary 119
- American Society for Reproductive Medicine (ASRM) endometriosis score 94–5
- 5-aminolevulinic acid (ALA) 57–8
- amitriptyline 111–12
- analgesic agents
 - adjuvant 111–12
 - chronic pelvic pain 111–12
 - dysmenorrhoea 87
 - endometriosis 96
- androgen excess 130, 132, 136
- androgen insensitivity syndrome 117
- anovulation 129
- anti-androgens 136
- antifibrinolytic drugs 39
- anti-Müllerian hormone (AMH)
 - 132–3
- anti-obesity drugs 134–5
- antiprogestogens 43
- anxiolytics 143
- aromatase inhibitors 98
- asoprisnil 43
- assisted conception 95, 124–5
- autoimmune disease 119–20, 122
- behavioural interventions,
 - dysmenorrhoea 87
- BEPS (benign edematous polysynovitis syndrome) 121
- bimanual examination 17
- biopsy
 - endometrial *see* endometrial biopsy/sampling
 - ovarian 120, 124
- bisphosphonates 125–6
- body weight *see* weight
- bowel
 - endometriosis involving 93
 - factors in chronic pelvic pain 107
 - surgical injury 59
- cancer patients 122–5
- cardiovascular disease 133
- Cavaterm endometrial ablation
 - system 52–4
- Cerazette 88, 96
- chemicals, environmentally/
 - hormonally active 116–17
- chemotherapy 122–5
- Chinese remedies 87
- chocolate cysts 91
- cholesterol desmolase deficiency 122
- chromosomal abnormalities 121
- chronic pelvic pain (CPP) 103–12
 - contributory factors 104–9

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- chronic pelvic pain (CPP) (cont.)
 - definitions and epidemiology 103
 - initial assessment 109–10
 - management 110–12
- clomifene citrate 135
- clotting (coagulation) defects 11–12, 14
- codeine 111
- coelomic metaplasia theory 92
- cognitive behavioural therapy (CBT) 143
- combined oral contraceptives (COC)
 - dysmenorrhoea 87–8
 - endometriosis 96
 - excessive menstrual bleeding 42
 - premature ovarian failure 125
 - premenstrual syndrome 143
- complementary and alternative therapies 87, 112, 126, 143–4
- constipation 107
- contraception
 - dysmenorrhoea 87–8
 - endometriosis 96–7
 - polycystic ovary syndrome 135
 - premature ovarian failure 125
- coronary heart disease 133
- cryosurgical endometrial ablation 57
- cyclo-oxygenase-1 (COX-1) inhibitors 38–9
- cyproterone acetate 136
- cystitis, interstitial 107
- danazol 42, 98, 142–3
- Depo-Provera 42, 87, 96–7
- depression 105, 109
- diabetes, type 2 133
- Dianette 136
- diet
 - menarcheal age and 116
 - polycystic ovary syndrome 134
- dilatation and curettage (D&C) 17–19
 - efficacy 18–19
 - safety 19
 - as treatment 32
 - versus hysteroscopy 23
- Doppler ultrasound 28–30
- Down syndrome 121
- drug treatment *see* medical management
- dyschezia 93
- dysfunctional uterine bleeding (DUB) 10–11
- dysmenorrhoea 4–5, 83–8
 - assessing the patient 85–6
 - definition and epidemiology 83–4
 - endometriosis-related 84–5, 93
 - investigation 86–7
 - management 87–8
 - potential causes 84–5
 - primary 5, 83–4
 - secondary 5, 83–4
- dyspareunia 86, 93
- eflornithine 136
- endocrine disorders 12
- endometrial ablation 47–58
 - complications 51–3
 - cryosurgical 57
 - first-generation techniques 49–52
 - patient selection and outcomes 48–9
 - second-generation techniques 49, 52–8
 - thermal balloon 53–4
- endometrial biopsy/sampling 14, 22
 - hysteroscopically directed 22–4
 - outpatient 30–1
- endometrial carcinoma
 - diagnosis 18–19, 26–7, 29, 31
 - investigation to exclude 32
 - polycystic ovary syndrome and 133
- endometrial hyperplasia 31
- endometrial laser ablation (ELA) 47–52
- endometrial laser intrauterine
 - thermotherapy (ELITT) 52, 58
- endometrial polyps 27, 32
- endometrial thickness, ultrasound measurement 26
- endometriomas 91, 94, 98
- endometriosis 91–100
 - aetiology 92–3

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- diagnosis 94–5
- nature of 91–2
- pelvic pain 93, 105–6
- staging 94–5
- symptoms 84–5, 93–4
- treatment 95–9
- endometrium
 - dating 7–8
 - hysteroscopic appearances 22–4
 - morphology 7–8
- enzyme deficiencies 121–2
- 17 β -estradiol 125
- estrogen
 - deficiency, symptoms 119
 - fibroid growth and 71
 - patches, premenstrual syndrome 143
 - premenstrual syndrome
 - pathogenesis 139–41
 - replacement therapy 125
- estrogen/progestogen combinations
 - excessive menstrual bleeding 42
 - premature ovarian failure 125
 - premenstrual syndrome 143
- etamsylate 39
- eVALuate study 47, 59–61
- evening primrose oil 143–4
- examination, clinical 14, 17–18
- excessive menstrual bleeding 7–15
 - aetiology 9–12
 - management 13–15
 - medical management 37–44
 - patient information and choice 43
 - surgical management 47–63
- exercise
 - intense, and menarcheal age 116
 - polycystic ovary syndrome 134
- fat, body 116
- fenamates 39
- fertility/infertility
 - endometriosis and 84, 94–5, 99
 - polycystic ovary syndrome
 - 135–6
 - premature ovarian failure and 124–5
 - uterine fibroids and 71
- fibroids, uterine
 - diagnosis 69–70
 - dysmenorrhoea 85
 - factors controlling growth 71–2
 - fertility and 71
 - heavy menstrual bleeding 12, 70–1
 - high-intensity focused ultrasound 78–9
 - medical treatment 74–5
 - surgical treatment 69, 72–4
 - treatment 72–9
 - uterine artery embolisation 75–8
 - uterine artery occlusion 79
- finasteride 136
- flooding 3, 10
- fluoxetine 142
- flutamide 136
- follicle-stimulating hormone receptor
 - gene polymorphism 121
- Food and Drug Administration (FDA) 53
- fragile X premutations 121
- free androgen index (FAI) 132, 134
- gabapentin 112
- galactosaemia 122
- genital tract, developmental
 - abnormalities 84, 117
- gestrinone 42
- glucose tolerance, impaired 131, 134
- gonadotrophin-releasing hormone (GnRH) analogues
 - chronic pelvic pain 112
- dysmenorrhoea 88
- endometriosis 97
- excessive menstrual bleeding 42–3
- premenstrual syndrome 142
- prior to endometrial ablation 49
- uterine fibroids 73–4
- gonadotrophin therapy, polycystic ovary syndrome 136
- Gynecare Thermachoice 52–4
- haematocolpos 84, 117
- haematometra 51

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- heavy menstrual bleeding (HMB) 2–3, 9–12
 - aetiology 9–12
 - defined 2, 9
 - fibroid-associated 12, 70–1
 - management 13–15
 - medical management 37–44
 - terminology 2, 9
- Her Option endometrial cryoablation 53, 57
- herbal remedies 87, 143–4
- high-intensity focused ultrasound, uterine fibroids 78–9
- hirsutism 130, 136
- history, clinical 13–14, 17–18
- hormonal treatments
 - endometriosis 96–8
 - excessive menstrual bleeding 37, 40–3
 - premenstrual syndrome 142–3
- hormone replacement therapy (HRT)
 - after hysterectomy 99
 - combined with GnRH analogues (add-back) 97
 - excessive menstrual bleeding 42
 - premature ovarian failure 125
- HRT *see* hormone replacement therapy
- Hydro ThermAblator 52–3, 56–7
- 17 α -hydroxylase deficiency 122
- hymen, imperforate 84
- hyperandrogenism 130, 132, 136
- hysterectomy 13–14, 58–62
 - for chronic pelvic pain 112
 - complications 58–9
 - for dysmenorrhoea 88
 - for endometriosis 99
 - for heavy menstrual bleeding 37
 - laparoscopic 59–61
 - oophorectomy at 62
 - ovarian failure after 123
 - subtotal 61–2
 - for uterine fibroids 69, 72–3
 - women's expectations 1
- hysteroscopy 19–24
 - efficacy 22
 - for endometrial ablation 52–3, 56–7
 - equipment 20–1
 - safety 23
 - technique 21–4
 - as treatment 32
 - versus D&C 23
- Implanon 87, 96–7
- in vitro fertilisation (IVF) 95, 124–5
- infections, causing ovarian failure 123
- infertility *see* fertility/infertility
- inhibin gene mutation 121
- insulin resistance 131–2
- intermenstrual interval
 - normal 3–4, 8
 - reduced 12–13
- interstitial cystitis 107
- intrauterine contraceptive devices (IUCDs) 12
- investigations 14, 17–33
- iron therapy 37
- irregular menstrual bleeding
 - see* menstrual irregularity
- irritable bowel syndrome 86, 107, 111
- laparoscopic assisted vaginal hysterectomy (LAVH) 59–60
- laparoscopic hysterectomy 59–61
- laparoscopic ovarian diathermy 136
- laparoscopic uterosacral nerve ablation (LUNA) 88, 112
- laparoscopy
 - diagnostic 84, 94, 110
 - endometriosis ablation 98–9
- laparoscopy and dye test 84
- leiomyomata, uterine *see* fibroids, uterine
- leiomyosarcoma 29, 69
- leptin 116
- leukotrienes 85
- levonorgestrel-releasing intrauterine system (LNG-IUS) (Mirena) 40–1
 - dysmenorrhoea 87
 - endometriosis 96
 - uterine fibroids 74
- luteinising hormone (LH), elevated levels 131

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- magnetic resonance imaging (MRI)
 - dysmenorrhoea 84
 - endometriosis 95
 - guided high-intensity focused ultrasound 78–9
 - uterine fibroids 69–70
- management, menstrual complaints 13–15
- matrix metalloproteinases 9
- medical management
 - dysmenorrhoea 87–8
 - excessive menstrual bleeding 37–44
 - uterine fibroids 74–5
- Medicines and Healthcare Products Regulatory Agency 53
- medroxyprogesterone acetate (MPA)
 - depot (Depo-Provera) 42, 87, 96–7
 - for endometriosis 97–8
- mefenamic acid 39
- menarche 115
 - delayed 115–17
 - factors affecting age at 115–17
- menopause
 - early 119
 - irregular menstrual bleeding 4
 - premature *see* premature ovarian failure
- menorrhagia *see* heavy menstrual bleeding
- menstrual bleeding, excessive
 - see* excessive menstrual bleeding
- menstrual blood loss (MBL)
 - efficacy of drugs in reducing 38
 - excessive *see* heavy menstrual bleeding
 - measurement 3, 17–18
 - normal range 10
- menstrual cycle
 - endometrial changes 7–8
 - normal length 3–4, 8
- menstrual intolerance 3
- menstrual irregularity 4, 13
 - dysmenorrhoea with 85–6
 - polycystic ovary syndrome 129, 135
- menstruation 7
 - abnormal 5, 7–15
 - mechanism 8–9
 - retrograde 92
- metformin 135–6
- microwave endometrial ablation (MEA) 52–5
- mifepristone 43
- Mirena *see* levonorgestrel-releasing intrauterine system
- MISTLETOE study 47, 51
- mumps 123
- musculoskeletal factors, chronic pelvic pain 108
- myomectomy 69, 72–4
- National Institute for Health and Clinical Excellence (NICE)
 - guideline 1, 32, 40–1, 47
- nerve entrapment 108
- neuropathic pain 108–9, 111–12
- non-steroidal anti-inflammatory drugs (NSAIDs)
 - chronic pelvic pain 111
 - dysmenorrhoea 87
 - endometriosis 96
 - excessive menstrual bleeding 38–9
 - premenstrual syndrome 143
- norethisterone 41, 97–8
- NovaSure endometrial ablation device 52–3, 55–6
- NSAIDs *see* non-steroidal anti-inflammatory drugs
- obesity 131
- oocyte donation 124
- oophorectomy 62, 88, 99, 123, 142
- orlistat 134–5
- ovarian biopsy 120, 124
- ovarian cysts 41, 91
- ovarian diathermy, laparoscopic 136
- ovarian failure, premature
 - see* premature ovarian failure
- ovarian hyperstimulation syndrome 136
- ovarian reserve tests 124
- ovulation induction 124–5, 135

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- pain
 - defined 103
 - endometriosis 93
 - referred 105
- paracetamol 87, 96, 111
- paroxetine 142
- pelvic inflammatory disease (PID) 85, 106–7
- pelvic pain
 - chronic *see* chronic pelvic pain
 - endometriosis 93, 105–6
 - see also* dysmenorrhoea
- pelvic pathologies, heavy menstrual bleeding 12
- photosensitisation, endometrial ablation 57–8
- Pipelle endometrial sampler 30–1
- POF1/POF2 genes 121
- polychlorinated/polybrominated biphenyls 117
- polycystic ovarian syndrome (PCOS) 129–36
 - clinical features 129
 - endocrine and metabolic features 131–2
 - investigations 133–4
 - long-term health risks 133
 - pathophysiology 132–3
 - Rotterdam criteria 129
 - treatment 134–6
- polycystic ovaries 129–31
- polyglandular failure syndromes 120
- polymenorrhoea 12–13
- post-tubal sterilisation syndrome 51
- post-TURP syndrome 50
- postmenopausal bleeding, investigation 18, 26–7
- pregnancy, after endometrial ablation 52
- premature ovarian failure (POF) 119–26
 - aetiology 120–3
 - familial 121
 - fertility and contraception 124–5
 - investigation 123–4
 - management 125–6
- primary 120–2
 - secondary 122–3
 - symptoms and health consequences 119–20
- premenstrual dysphoric disorder (PMDD) 139–40
- premenstrual syndrome (PMS) 139–44
 - aetiology 139–41
 - assessment 141
 - treatment 141–4
- presacral neurectomy 88, 112
- presentation, of menstrual problems 2–5
- Progestasert intrauterine system 40
- progesterone
 - endometrial responses 8–9
 - fibroid growth and 71–2
 - for premenstrual syndrome 143
 - premenstrual syndrome pathogenesis 139–41
- progesterone receptor modulators 43, 74–5
- progestogen-only oral contraception 96
- progestogens
 - for dysmenorrhoea 87–8
 - for endometriosis 96–8
 - for excessive menstrual bleeding 40–2
 - intramuscular (depot) 42
 - intrauterine 40–1
 - oral 41
 - for premenstrual syndrome 143
- prolactin, serum 134
- prostaglandins 8, 12, 85
- psychological factors, chronic pelvic pain 109
- pyridoxine 143
- radiotherapy 122–5
- raloxifene 125–6
- retained ovary syndrome 88
- retrograde menstruation 92
- rollerball endometrial ablation (RBEA) 49–51
- RU-486 43

Cambridge University Press

978-1-107-67738-8 - Menstrual Problems for the MRCOG and Beyond: Second Edition

Mary Ann Lumsden and Margaret Rees

Index

[More information](#)

- St John's wort 143–4
- Scottish Audit of Hysteroscopic Surgery 47–8, 51
- selective serotonin reuptake inhibitors (SSRIs) 142
- sertraline 142
- sex hormone-binding globulin (SHBG) 131–2, 134
- sexual abuse 109
- sexually transmitted infections (STI) 85, 106–7
- sibutramine 134–5
- sleep disturbance 105, 109
- spironolactone 136, 143
- strontium ranelate 125–6
- subfertility *see* fertility/infertility
- surgical treatment 47–63
 - chronic pelvic pain 112
 - dysmenorrhoea 88
 - endometriosis 95, 98–9
 - uterine fibroids 69, 72–4
- symphysis pubis dysfunction 108
- testicular feminisation 117
- testosterone
 - replacement therapy 125
 - serum levels 131–2, 134
- thrombocytopenia 11
- tranexamic acid 39
- transcervical resection of endometrium (TCRE) 48–52
- transcutaneous electrical nerve stimulation (TENS) 87
- transvaginal ultrasound 25–6
- trigger points 108
- trisomy 21 121
- tuberculosis 123
- Turner syndrome 117, 121, 124
- ulipristal 43
- ultrasound imaging 14, 25–8
 - diagnosis 26–7
 - Doppler 28–30
 - efficacy 27
 - endometriosis 95
 - equipment 25–6
 - polycystic ovary syndrome 130–1, 133
 - safety 27
 - technique 26
 - transvaginal 25–6
- ultrasound therapy, uterine fibroids 78–9
- urinary tract, surgical damage 59
- uterine artery embolisation (UAE) 75–8, 123
- uterine artery occlusion 79
- uterine cavity evaluation 17–33
 - indications 31–3
 - techniques 18–31
- uterus
 - congenital anomalies 84
 - referred pain 105
- Vabra endometrial aspirator 30
- vaginoscopy, no-touch 21
- VALUE hysterectomy study 47, 58–9, 61
- Vesta system 53
- viscero-somatic mapping 105
- viscero-visceral mapping 105
- vitamin B6 143
- von Willebrand's disease 11, 14
- weight
 - management, polycystic ovary syndrome 134–5
 - menarcheal age and 116